ALPMF — Astellas Pharma, Inc.
Is ALPMF overbought or oversold? Here is the current MarketMoodz read.
Astellas Pharma, Inc. (ALPMF) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - General) last closed at $17.50. The rating moved from Neutral to Overbought on November 14, 2026.
- Public ratingOverbought (as of November 17, 2026)
- Last close$17.50
- Last changeMoved from Neutral to Overbought on November 14, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - General
See all overbought Healthcare stocks →
AI analysis
Astellas Pharma, Inc. (ALPMF) presents a stable, diversified commercial base anchored by established specialty franchises and a pipeline with late-stage assets that could provide incremental upside. Current sector flows favor large-cap pharma defensiveness, which supports valuation stability. The company’s cash generation and balance-sheet flexibility underpin the ability to pursue targeted M&A or investment in growth programs, while distributor and specialty pharmacy trends should sustain prescription volumes. Near-term performance is contingent on clinical readouts and execution against commercial growth initiatives; limited social sentiment and filings information are available in the current window.
Key factors
- Diversified commercial portfolio with established oncology, urology and specialty care franchises that provide recurring cash flow and revenue stability
- Sector tailwinds for large-cap pharma driving defensive ETF flows and investor interest, supporting valuation resilience in risk-off periods
- Late-stage pipeline and near-term clinical/commercial catalysts that could drive upside to revenue and sentiment if positive
- Solid balance-sheet characteristics and cash generation that enable targeted M&A or bolt-on deals to bolster growth
- Favorable distributor and specialty pharmacy trends that support sustained prescription flows for injectable and specialty products
- Limited immediate macro/regulatory shocks reported in the market window, enabling consolidation rather than volatility in stock movement
Risks
- Clinical or regulatory setbacks in key pipeline programs or label changes that could materially reduce future revenue expectations
- Patent expirations or faster-than-expected generic entry on key products leading to rapid revenue erosion
- Pricing pressure and reimbursement headwinds from payors and potential policy changes that could compress margins
- Currency exposure and geopolitical risks given the company’s international footprint (translation and economic impacts)
- Operational risks including manufacturing, supply-chain disruptions, or issues with specialty distribution partners
- Concentration risk if a small number of products account for a large portion of revenues; adverse outcomes could be outsized
See today's live rating, score and targets
Members see the live hourly rating for ALPMF — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.